Core Insights - Sands Capital Select Growth Strategy reported a portfolio return of 6.3% in Q3 2025, underperforming the benchmark's 10.5% gain, driven by strong corporate earnings and AI enthusiasm [1] - DexCom, Inc. (NASDAQ:DXCM) faced a one-month return of -8.29% and a 52-week decline of 19.94%, closing at $62.53 with a market cap of $24.52 billion [2][3] Company Performance - DexCom, Inc. is a leading producer of glucose monitors, experiencing stock price pressure due to industry weakness and scrutiny over product reliability [3] - Despite challenges, DexCom has shown accelerating year-over-year revenue growth for three consecutive quarters, with Q3 2025 global revenue reaching $1.21 billion, up from $994 million in Q3 2024 [4] Future Outlook - Management raised 2025 revenue guidance cautiously, which disappointed investors, but this conservative approach may allow for upside potential in the latter half of 2025 [3] - Potential catalysts for DexCom include strong adoption of its new 15-day sensor, expanded Medicare coverage, and clarity on long-term plans, with expectations for margin leverage contributing to profitability in 2026 [3]